Assessment and Management of Heart Failure with Preserved Ejection Fraction (HFpEF)
This patient has heart failure with preserved ejection fraction (HFpEF) confirmed by elevated filling pressures (LVEDP 24 mmHg, PCWP 18 mmHg), preserved EF (60%), and increased relative wall thickness (0.44), presenting with classic congestive symptoms—immediate treatment should focus on decongestion with loop diuretics and initiation of SGLT2 inhibitors (empagliflozin or dapagliflozin) as disease-modifying therapy. 1, 2
Initial Clinical Assessment
The heart failure clinic should immediately recognize this as HFpEF with elevated filling pressures based on:
- Hemodynamic confirmation: LVEDP 24 mmHg and PCWP 18 mmHg both exceed normal thresholds (normal LVEDP <12 mmHg, PCWP <12 mmHg), definitively establishing elevated left ventricular filling pressures 3
- Preserved systolic function: EF 60% meets HFpEF criteria (≥50%) 2
- Structural abnormality: Relative wall thickness 0.44 indicates concentric remodeling (normal ≤0.42), suggesting hypertensive heart disease or hypertrophic response 4
- Congestive symptoms: Orthopnea, fluid retention, and chronic dry cough represent volume overload requiring immediate intervention 5, 6
Key Diagnostic Confirmation Steps
The clinic should obtain:
BNP or NT-proBNP levels to quantify disease severity and establish baseline for monitoring 2, 3
Comprehensive echocardiography including:
- E/e' ratio (average septal and lateral e') to assess filling pressures non-invasively 3
- Left atrial volume index (LAVi) - values ≥34 mL/m² indicate chronically elevated pressures 4
- LV mass index to quantify hypertrophy
- Tissue Doppler velocities (e' <7 cm/s septal or <10 cm/s lateral suggests diastolic dysfunction) 3
Exclude specific etiologies requiring targeted therapy 1:
- Cardiac amyloidosis (technetium pyrophosphate scan if wall thickness disproportionate to hypertension history)
- Hypertrophic cardiomyopathy (if unexplained severe hypertrophy)
- High-output states (check thyroid function, assess for arteriovenous malformations)
Immediate Management: Decongestion
Start intravenous loop diuretics without delay - early intervention improves outcomes in decompensated heart failure 7:
- Initial dose: If diuretic-naive, start furosemide 20-40 mg IV; if already on oral diuretics, use IV dose equal to or exceeding daily oral dose 5
- Administration: Either intermittent boluses or continuous infusion are acceptable; titrate based on urine output and symptom relief 5
- Monitoring: Daily weights, strict intake/output, daily electrolytes (potassium, creatinine, BUN) during active diuresis 7
Intensification Strategy if Inadequate Response
If congestion persists despite initial diuretic therapy 7:
- Increase loop diuretic dose
- Add second diuretic (metolazone 2.5-5 mg daily, or spironolactone 25 mg daily)
- Consider continuous furosemide infusion
- Add acetazolamide 500 mg IV if patient not on SGLT2 inhibitor (ADVOR trial showed superior decongestion) 6
Critical caveat: Avoid excessive diuresis causing hypotension or worsening renal function, as HFpEF patients are preload-dependent 8
Disease-Modifying Pharmacotherapy
First-Line: SGLT2 Inhibitors (Class I Recommendation)
Initiate empagliflozin 10 mg daily or dapagliflozin 10 mg daily before hospital discharge or at first outpatient visit 1, 2:
- Evidence: EMPEROR-PRESERVED and DELIVER trials demonstrated 21% reduction in cardiovascular death or HF hospitalization 1
- Mechanism: Reduces congestion, improves cardiac remodeling, benefits independent of diabetes status
- Monitoring: Check renal function (can use if eGFR ≥20 mL/min/1.73m²), monitor for volume depletion initially
Second-Line: Mineralocorticoid Receptor Antagonists
Add spironolactone 25 mg daily (or eplerenone 25 mg daily if gynecomastia concerns) 1, 2:
- Indication: Particularly if patient has hypertension, hypokalemia, or requires potassium supplementation
- Monitoring: Check potassium and creatinine within 1 week, then monthly for 3 months
- Contraindications: Potassium >5.0 mEq/L, eGFR <30 mL/min/1.73m²
- Prefer MRA over potassium supplements for maintenance therapy 6
Consider: Angiotensin Receptor-Neprilysin Inhibitor (ARNI)
Sacubitril/valsartan may be considered if patient has:
- LVEF closer to 50% (more benefit in HFmrEF range)
- Elevated natriuretic peptides
- Younger age with fewer comorbidities 1, 2
Start 24/26 mg twice daily, titrate to 97/103 mg twice daily as tolerated. Monitor blood pressure and renal function closely.
Blood Pressure and Comorbidity Management
Hypertension Control
Given the concentric remodeling (RWT 0.44), aggressive blood pressure control is essential:
- Target: <130/80 mmHg 4
- Agents: ACE inhibitors or ARBs are reasonable for hypertension control (though not proven to reduce HFpEF mortality) 8, 2
- Beta-blockers: Use only if specific indication (prior MI within 3 years, angina, atrial fibrillation rate control) - may worsen exercise tolerance due to chronotropic incompetence 1
Address the Chronic Dry Cough
Investigate and treat potential causes:
- ACE inhibitor-induced: If on ACE inhibitor, switch to ARB
- Pulmonary congestion: Should improve with decongestion
- Pulmonary hypertension: Check tricuspid regurgitation velocity on echo; if elevated, consider right heart catheterization to differentiate post-capillary from pre-capillary pulmonary hypertension 9
Non-Pharmacological Management
Exercise Training (Class I Recommendation)
Prescribe supervised aerobic exercise program 5, 2:
- Improves functional capacity and quality of life
- Start with 20-30 minutes, 3-5 times weekly
- Gradually increase intensity as tolerated
Weight Management
If BMI ≥30 kg/m²:
- Target 5-10% weight loss through caloric restriction and exercise 1, 10
- Consider referral to structured weight management program
Multidisciplinary Care Enrollment
Enroll in heart failure disease management program (Class I recommendation) 5, 2:
- Reduces HF hospitalizations and mortality
- Provides education on daily weights, dietary sodium restriction (<2-3 g/day), medication adherence
- Facilitates early intervention for decompensation
Monitoring Strategy
Outpatient Follow-up Schedule
- Week 1-2: Assess diuretic response, check electrolytes and renal function
- Month 1: Titrate GDMT, reassess symptoms (NYHA class), repeat BNP
- Month 3: Comprehensive reassessment including repeat echocardiography to evaluate:
- E/e' ratio improvement
- Left atrial volume reduction
- Response to therapy
Red Flags Requiring Urgent Reassessment
- Worsening dyspnea despite therapy
- Weight gain >2 kg in 3 days
- Worsening renal function (creatinine increase >0.3 mg/dL)
- Hypotension with symptoms
- New arrhythmias (particularly atrial fibrillation)
Common Pitfalls to Avoid
Over-diuresis: HFpEF patients are exquisitely sensitive to preload reduction; excessive diuresis causes hypotension and prerenal azotemia 8
Assuming normal BNP excludes HFpEF: Obesity and chronic stable HFpEF may have "normal" BNP despite elevated filling pressures 11, 3
Delaying SGLT2 inhibitor initiation: This is the only proven mortality-reducing therapy in HFpEF - start early 1, 2
Using HFrEF dosing targets: HFpEF patients often cannot tolerate aggressive neurohormonal blockade due to blood pressure limitations
Ignoring atrial fibrillation: If present, requires rate control (target <110 bpm at rest) and anticoagulation assessment 1
This algorithmic approach prioritizes immediate symptom relief through decongestion while simultaneously initiating evidence-based disease-modifying therapy with SGLT2 inhibitors, addressing the underlying pathophysiology of elevated filling pressures and concentric remodeling in this HFpEF patient.